In a 20 mL cartridge filling suite, the V9621 pharma-grade elastomer compound supplied as the Datwyler NeoFlex™ cartridge plunger enters the barrel only after the liquid fill reaches target weight. Automatic plunger insertion stations generally apply vacuum to the barrel headspace before seating, maintaining residual headspace oxygen within process-defined limits for oxygen-sensitive parenterals. The insertion stroke is controlled by servo-driven pick-and-place tooling with compression force limits and depth confirmation by vision or linear variable differential transformer feedback. Because the plunger does not seal until its ribs contact the glass bore, insertion depth and perpendicularity directly influence final headspace volume and the probability of plunger tilt. In cartridge lines handling aqueous injectables, the V9621 material is washed and, if required, siliconized before insertion; a bulk water-for-injection rinse is applied to reduce the extractable load contributed by surface residues. Production data from 20 mL filling lines show that deviations in plunger rib concentricity exceeding the supplier-specified tolerance can increase insertion force variability, although published values specific to V9621 are limited. The dimensional stack-up is verified against ISO 11040-4:2015 for the glass barrel and the supplier specification for the plunger drawn from ISO 11040-6. The fill-and-stop setup includes routine leak testing of sealed cartridges using vacuum decay or dye ingress as defined in the cartridge assembly specification, rather than relying on the plunger certificate alone.

What Does USP <381> Require for an Aqueous Autoclavate of a V9621 Plunger?

The extractables profile of V9621 in a 20 mL cartridge plunger is evaluated in pharmacopeial extraction media. Compounded elastomer articles are generally tested according to ISO 8871-1:2003, which specifies aqueous autoclavates and defined extraction procedures, while USP <381> applies to elastomeric closures for injections and includes physicochemical and biological test requirements. For cartridge assemblies that remain in contact with the drug solution over prolonged storage, the leachables assessment moves from the compendial extractables screen to a drug-product-specific study under USP <1663> and USP <1664>. The key variables are pH, ethanol or propylene glycol content, buffer species, storage temperature, and contact surface area. Low-pH solutions such as citrate-based injectables can increase the extraction of metal ions from rubber curing residues; neutral or high-pH formulations may affect organic leachables differently. Because V9621 is a pharma-grade elastomer, its batch release documentation includes extractable heavy metals, reducing substances, and total organic carbon. Published data for V9621 in specific lipophilic or high-alcohol formulations are limited; a water-based extractables profile cannot be transferred to a formulation containing polysorbate or benzyl alcohol without a dedicated leachable study. Compendial compliance does not eliminate the requirement for actual drug-product stability data when the cartridge is in direct contact with the solution for more than 30 days.

When Final Sterilization Is Performed in a Steam-Air Mixture at 121 °C

Terminal sterilization of a pre-filled 20 mL cartridge imposes an additional thermal history on V9621. In a typical overpressure retort cycle, the cartridge is held at 121 °C for 15 min to 20 min. During the heating phase, the elastomer plunger expands against the borosilicate glass barrel; upon cooling, the plunger must recover its original rib compression to maintain the primary seal. Compression set after autoclaving is a critical parameter, measured in accordance with ISO 815-1:2019 or supplier-defined methods. If the plunger loses more than the permissible compression set, a reduction in radial seal force can create a path for microbial ingress or gas exchange. Equally, if the silicone oil used to reduce insertion force migrates or redistributes during steam sterilization, the break-loose force may shift after cooling. A documented processing boundary is that cycloolefin or polycarbonate cartridge bodies cannot be subjected to conventional terminal steam cycles unless specifically designed for such temperatures; borosilicate glass barrels conforming to ISO 11040-4:2015 are the standard mating component. Published data for V9621 compression set after extended exposure to steam-air mixtures are limited; each combination of barrel internal diameter, sterilization cycle, and fill volume requires force testing after sterilization. The functional force test is executed on a universal testing machine using a crosshead speed defined in the manufacturer's test procedure or ISO 11040-6.

Subcutaneous delivery of large-volume biologic formulations through wearable or patch-type injectors has introduced a 20 mL cartridge format in which the V9621 plunger moves at a variable travel speed over several minutes. High-viscosity formulations, such as concentrated monoclonal antibody solutions, require controlled plunger acceleration to avoid cavitation and dose inaccuracy. The gliding force is influenced by the interference fit between the plunger ribs and the cartridge bore, the coefficient of friction of any surface lubricant, and the rheological profile of the solution. At the cartridge level, the functional requirement is expressed as break-loose force and glide force, tested with a universal testing machine according to ISO 11040-6. In high-viscosity applications, the plunger can exhibit stick-slip motion if static friction is excessively high; this condition is more likely with low-siliconized or texture-modified elastomer surfaces. The V9621 surface finish and the barrel siliconization specification are therefore linked. Extractable silicone oil is covered by USP <381> and the manufacturer's silicone specification. Because these cartridge systems are often used for protein formulations, the drug product sponsor must evaluate protein aggregation caused by silicone oil droplets or elastomer leachates. Relevant methods include subvisible particle analysis by light obscuration per USP <787> and size-exclusion chromatography. Published data for V9621 in high-viscosity protein cartridges are limited; process development must generate cartridge-specific force and aggregation data.

Solvent Swell and Dimensional Recovery in Multi-Dose Veterinary Injector Cartridges

Large-volume veterinary cartridges filled with anti-infective or parasiticide formulations often contain non-aqueous co-solvents such as benzyl alcohol, propylene glycol, or N-methylpyrrolidone. The V9621 plunger must maintain seal integrity after prolonged exposure to these vehicles. Volume swell is measured according to ASTM D471-16a, in which the rubber specimen is immersed in the formulation or a reference liquid for a defined period and the change in volume, mass, and tensile properties is determined. For a cartridge plunger, excessive volume swell expands the ribs and can raise insertion force or produce dimensional interference; excessive shrinkage after extraction of a plasticizer leads to seal leakage. In multi-dose veterinary injector devices, the plunger may be advanced repeatedly over a dosing schedule, so dynamic friction after solvent exposure is more relevant than single-break-loose force. Compounds used in veterinary injectables may also contain strong oxidizing or reducing agents; the elastomer formulation is screened for oxidative degradation under ISO 8871-2:2003 identification and hardness methods. Regulatory acceptance is anchored in ISO 8871-1:2003 for autoclavate extractables and USP <381> for physicochemical properties. Published data for V9621 in specific veterinary co-solvent matrices are limited; a compatibility study using the complete drug product is necessary before lot-to-lot variation can be evaluated.

Diagnostic injectable drugs, including iodinated contrast media and gadolinium-based magnetic resonance contrast agents, can be supplied in cartridge-compatible reservoirs for powered injectors. In this setting, a 20 mL cartridge plunger is exposed to a rapid pressure increase and a high peak hydraulic pressure during contrast delivery. The primary seal must not fail when the cartridge barrel is pressurized in a piston-driven injector; the burst resistance of the glass barrel is generally verified under ISO 11040-4:2015. For the elastomer plunger, the critical test is to maintain a leak-tight seal while moving at the injector's prescribed flow rate. Contrast media formulations often have high iodine content and may include salts such as sodium citrate or edetate calcium disodium; these can affect extractables and surface friction. Some contrast injectors use dedicated fill kits or pre-filled syringes, so cartridge compatibility is verified for the exact barrel coating and siliconization. Dimensional control of the plunger sealing ribs is critical because pressure-driven deformation can flatten the ribs and reduce contact pressure. The release of elastomer particles under high shear is measured using the particulate limits in USP <788> after simulated delivery. Published data for V9621 used in high-pressure contrast injector systems are limited; the plunger is not qualified by a static storage compatibility study alone. The application includes dynamic leak testing at a pressure defined by the injector's maximum mechanical output rather than by a generic pharmacopeial dye-ingress test.

Elastomer Particulate Burden Is Controlled by USP <788> and ISO 8871-3 at the Plunger Rib Level

Particulate release from a cartridge plunger is not solely a bulk compound property; it is influenced by rib geometry, molding flash, curing residues, and downstream washing. For injectable cartridges, the final solution must meet USP <788> subvisible particulate limits and USP <790> visible particulate requirements. The elastomer component itself is evaluated by ISO 8871-3:2003, which describes methods for released-particle count from elastomeric parts. In a 20 mL cartridge, particles shed from the plunger can appear in the drug product as loose elastomer fragments or as silicone oil droplets carrying rubber particles. The molding process for a plunger involves high-temperature compression or injection molding; flash left at the rib edges can detach during plunger insertion or during travel. For this reason, the supplier maintains a defined particle washing process and reports a total released-particle count from the cleaned component. Incoming-quality inspection at the filling site includes optical microscopy and, where appropriate, scanning electron microscopy with energy-dispersive X-ray spectroscopy to identify silicone and rubber fragments. The particle limit is defined by the pharmacopeial chapter rather than by the supplier's bulk certificate; a low extractable profile does not guarantee low particle release. If the plunger is siliconized, the silicone oil type and layer thickness must be controlled because the resulting silicone droplets may be counted as subvisible particles in USP <788> Method 1 or Method 2. Published particle data for V9621 are product-specific and must be generated with the exact washing train, siliconization level, and insertion equipment.

The V9621 cartridge plunger has no direct function in tablet compression, capsule filling, or granule processing. Its only relevant oral-pharmaceutical exposure is a 20 mL liquid reservoir intended for oral syringe administration, where the elastomer is in contact with aqueous oral solutions containing sorbitol, glycerol, sucrose, or low concentrations of ethanol. The extraction profile differs from parenteral because compendial limitations for oral liquids are less stringent than for injections, but the risk of extractables migration remains. Evaluation of the plunger for oral liquid use is typically anchored to 21 CFR 177.2600 for rubber articles intended for repeated use, with additional leachable testing where the product is administered to pediatric populations. If the same V9621 compound also meets parenteral requirements under USP <381> and ISO 8871-1:2003, it can be assigned to an oral liquid cartridge line only after confirming that sweetener and flavor interactions do not alter volume swell or surface friction. The component is not exposed to dry granulation, roller compaction, or tablet coating; those sectors require no evaluation of this plunger format.